

PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DOUGLAS P. CERRETTI

Appln. No. 08/538,709

Group Art Unit: 1647

Filed: October 3, 1995

Examiner: Draper, G.

For: DNA ENCODING CYTOKINE DESIGNATED
LERK-6

Corrected
DECLARATION UNDER 37 C.F.R. § 1.131

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

I, DOUGLAS P. CERRETTI do hereby declare and state:

I am the inventor of the invention disclosed and claimed in the above-mentioned application.

I am familiar with U.S. Patent 5,795,734, issued to Flanagan on August 18, 1998 (hereinafter the "Flanagan Patent"), from U.S. Patent Application Serial No. 08/455,001, filed May 31, 1995 (hereinafter the "Flanagan Application"), which I understand is a Continuation-In-Part of Serial No. 08/393,461, filed February 27, 1995 (hereinafter the "Flanagan Parent Application"), which is a Continuation-In-Part of Serial No. 08/308,814, filed September 19, 1994 (hereinafter the "Flanagan Grandparent Application").

The Flanagan Patent discloses DNA encoding Elf-1, a mouse polypeptide which is now known in the art as mouse LERK-6.

In order to demonstrate and establish, *inter alia*, that I conceived and reduced to practice a DNA molecule encoding a polypeptide having mouse LERK-6 sequences in the United States by at least September 15, 1994, i.e., prior to the

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

September 19, 1994, filing date of the Flanagan Grandparent Application, copies of the following laboratory notebook pages and related materials, identified in detail below, are provided herewith in **Appendices A-G**.

I declare and state that although all of the dates from the laboratory notebook pages and related materials have been removed, all of the dates are prior to at least September 15, 1994.

Appendix A contains pages from Nicole Nelson's Laboratory Notebook No. 4266 (Bates Nos. 0001-0007). At the time, Nicole Nelson was a Research Assistant who worked under my direction and supervision at Immunex Corporation.

Appendix B contains a copy of U.S. Patent 5,516,658 (Bates Nos. 0008-0026).

Appendix C contains oligonucleotide request forms prepared by Carl Kozlosky (Bates Nos. 0027-0030). At the time, Carl Kozlosky was a Research Associate who worked under my direction and supervision at Immunex Corporation.

Appendix D contains pages from Carl Kozlosky's Laboratory Notebook No. 3388 (Bates Nos. 0031-0037).

Appendix E contains various computer printouts of LERK sequences that I personally generated (Bates Nos. 0038-0049).

Appendix F contains the minutes of an internal HEK/ELK meeting at Immunex Corporation that was chaired by Barry Davison in my absence (Bates Nos. 0050-0051). Barry Davison, who prepared the minutes, was the Director of the Transgenics Department at Immunex Corporation at the time.

Appendix G contains a copy of American Type Culture Collection Form BP4/9 for ATCC deposit No. 75829 (Bates No. 0052).

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

Prior to September 15, 1994, and as described in Example 1 of the present application, a DNA molecule encoding mouse LERK-6 was isolated under my direction and supervision. The specific experiments detailed below were carried out at my behest and command and under my direction and supervision by scientists at Immunex Corporation.

More specifically, prior to September 15, 1994, and as described at page 23, lines 5-7 of the present application, a commercially available 11.5 day murine embryonic cDNA library was obtained by Nicole Nelson from Clontech Laboratories, Inc., Palo Alto, California (Appendix A, Bates No. 0003).

Next, prior to September 15, 1994, and as described on page 23, lines 7-8 of the present application, the library was plated by Nicole Nelson according to the procedures detailed in the manual provided by Clontech (Appendix A, Bates No. 0004). The initial purpose of these efforts was to clone the cDNA for mouse LERK-3 (referred to as A2) and mouse LERK-4 (referred to as C6). However, instead a new mouse LERK molecule was discovered, i.e., mouse LERK-6.

Prior to September 15, 1994, and as described on page 23, lines 8-30 of the present application, probes, referred to as A2 (LERK-3) and C6 (LERK-4), were generated using standard techniques. Generally, polymerase chain reaction (PCR) (Mullis et al, Meth. Enzymol., 155:335-350 (1987)) amplifications were performed by Carl Kozlosky (Appendix D, Bates Nos. 0036-0037) using two sets of primers. The first set of primers,

GATATTTACT GCCCGCACTA CAACAGCT

SEQ ID NO:3

AGAGAAGGCG CTGTAGCGCT GGAAC

SEQ ID NO:4

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

was used to generate amplified double stranded DNA fragments from the DNA of LERK-3 (LERK-3, also known as hek-ligand, is the subject of ~~U.S.~~ Patent 5,516,658 (**Appendix B**, Bates Nos. 0008-0026) which issued from U.S. Patent Application Serial No. 08/240,124, filed May 9, 1994, and which claims benefit of Serial Nos. 08/109,745, 08/114,426 and 08/161,132). The probe from LERK-3 comprised nucleotides 260 through 481 of the SEQ ID NO:1 of U.S. Patent 5,516,658. The second set of primers,

ACGTAGTCTA CTGGAAGTCC AGTAACCCCA G SEQ ID NO:5

AGCCTCAAGC ACTGGCCAGA ACTCTCTCTG GAGT SEQ ID NO:6

was used to generate amplified double stranded DNA fragments from the DNA of LERK-4 (LERK-4 also is the subject of U.S. Patent 5,516,658). The probe from LERK-3 comprised nucleotides 110 through 467 of the SEQ ID NO:3 of U.S. Patent 5,516,658.

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:3, i.e., oligo #12334 (also referred to as A2rib5.28) (**Appendix C**, Bates No. 0027), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0027).

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:4, i.e., oligo #12333 (also referred to as A2T7.49) (**Appendix C**, Bates No. 0028), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0028).

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:5, i.e., oligo #12312

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

(also referred to as C6RIB05.31) (**Appendix C**, Bates No. 0029), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0029).

Prior to September 15, 1994, Carl Kozlosky requested that the core facility at Immunex Corporation synthesize the oligonucleotide represented by SEQ ID NO:6, i.e., oligo #12316 (also referred to as C6T7.54) (**Appendix C**, Bates No. 0030), and the core facility actually synthesized such prior to September 15, 1994, as shown in (**Appendix C**, Bates No. 0030).

Oligonucleotides #12333 and 12316 also included nucleotides encoding the T7 polymerase promoter.

Prior to September 15, 1994, Carl Kozlosky identified the location of oligonucleotides #12334 (A2rib5.28) and #12333 (A2T7.49) in the LERK-3 DNA sequence, as shown in **Appendix D**, Bates Nos. 0032-0033); as well as the location of oligonucleotides #12312 (C6RIB05.31) and 12316 (C6T7.54) in the LERK-4 DNA sequence, as shown **Appendix D**, Bates Nos. 0034-0035).

Thereafter, and prior to September 15, 1994, and as described on page 23, lines 30-35 of the present application, the PCR fragments (A2/LERK-3 and C6/LERK-4) were radiolabelled by Nicole Nelson with ³²P (**Appendix A**, Bates No. 0005), and used by Fred Fletcher as probes to screen the murine embryonic cDNA library prepared by Nicole Nelson by conventional procedures, and hybridizing clones were identified. Fred Fletcher was a Staff Scientist at Immunex Corporation at the time who worked on the LERK project under my direction and supervision. The hybridizing conditions consisted of 42°C and 50% Starks washed to 0.1X SSC at 63°C (**Appendix A**, Bates Nos. 0005-0006). In this manner, clone #13 was identified by Fred Fletcher on an X-ray

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

film, a copy of which was placed in Nicole Nelson's Laboratory Notebook (**Appendix A**, Bates No. 0007).

Then, and prior to September 15, 1994, and as described on page 23, line 35 and page 24, line 4, of the present application, the nucleotide sequence of the cDNA insert of clone #13 (λ 13), isolated from the murine embryonic cDNA library, i.e., mouse LERK-6 (mLERK6), was determined at my request by the core facility at Immunex Corporation, and the results were entered into a computer database, a printout of which, which was generated prior to September 15, 1994, is shown in **Appendix E**, Bates Nos. 0038-0039. DNA encoding the first ³/₅ amino acids shown in **Appendix E** is derived from the sequencing vector, as indicated by the mark between the ^{ninth nucleotide} ~~fifth~~ amino acid (Arg) and the ^{tenth nucleotide} ~~sixth~~ amino acid (Ala). Also, the initiation codon Met is not shown in **Appendix E**. Thus, a substantially complete cDNA sequence of the coding region of the clone λ 13 cDNA, and the amino acid sequence encoded thereby were determined, and are presented in SEQ ID NO:1 and SEQ ID NO:2, respectively of the present application. The open-reading frame within this sequence in **Appendix E** (and within SEQ ID NO:1) encodes a protein of 184 amino acids beginning with the ^{first} ~~second~~ Ala. cpc
8/7/2003

Prior to September 15, 1994, I carried out a comparison of the amino acid sequences of mouse LERK-6 v. human LERK-3 (also referred to as A2) (**Appendix E**, Bates No. 0040); mouse LERK-6 v. human LERK-4 (also referred to as C6) (**Appendix E**, Bates No. 0041); mouse LERK-6 v. human LERK-2 (also referred to as ELKL) (**Appendix E**, Bates No. 0042); mouse LERK-6 v. human LERK-5 (**Appendix E**, Bates No. 0043); mouse LERK-6 v. human LERK-1 (also referred to as B61) (**Appendix E**, Bates No. 0044); mouse LERK-6 v. mouse LERK-4 (also referred to as MC6) (**Appendix E**, Bates

DECLARATION UNDER 37 C.F.R. § 1.131
U.S. Appln. No. 08/538,709

No. 0045); as well as the DNA sequences for mouse LERK-6 v. human LERK-3 (A2) (**Appendix E**, Bates Nos. 0046-0047),); mouse LERK-6 v. mouse LERK-4 (MC6) (**Appendix E**, Bates No. 0048); and mouse LERK-6 v. human LERK-5 (**Appendix E**, Bates No. 0049). These comparisons showed many conserved amino acids and nucleotides amongst the family, and clearly showed that LERK-6 was a member of the LERK family of proteins, and thus would bind to hek/elk.

Prior to September 15, 1994, the results of the above-discussed experiments were presented by Nicole Nelson at an internal HEK/ELK meeting at Immunex Corporation. This meeting was chaired by Barry Davison in my absence, who prepared the meeting minutes, a copy of which is shown in **Appendix F** Bates No. 0050-0051.

Next, as described on page 24, lines 14-17 of the present specification, on July 15, 1994, a cell lysate containing clone λ 13 DNA (the LERK-6 cDNA in λ gt10) was deposited with the American Type Culture Collection, Rockville, MD, USA, and assigned accession number ATCC 75829. A copy of the deposit receipt is shown in **Appendix G**, Bates No. 0052.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

as Date: 2/20/01
Corrected 8/7/2003
Pg 6

Name: Douglas P. Cerretti
DOUGLAS P. CERRETTI

- 7 - Douglas P. Cerretti

NOTEBOOK NO. 4266
ISSUED TO Nicola Nelson
ON _____ 19____
DEPARTMENT Adm.
RETURNED _____ 19____

—SCIENTIFIC NOTEBOOK CO.—
2831 LAWRENCE AVE.
P.O. BOX 238
STEVENSVILLE, MI 49127
616-429-8285

0001

IMMUNEX LABORATORY NOTEBOOK

"TABLE OF CONTENTS" FORM

Notebook #: 4216

Date form completed:

Form Completed by: David Nelson

MOLECULE(S): C MGF

~~HEK~~

HEK

AIK

LEAK 4

LEAK 3

PROJECT(S):

Product Analysis Certificate

PRODUCT: Mouse Embryo 5'-STRETCH cDNA Library

CAT. #: ML1027a

LOT #: 1211

STORAGE CONDITIONS:
SHORT-TERM STORAGE (< 6 MONTHS)
4°C

LONG-TERM STORAGE (> 6 MONTHS)
-70°C

SHELF LIFE:
1 year from date of receipt under
proper storage conditions

SHIPPING CONDITIONS:
Dry Ice (-70°C)

PACKAGE CONTENTS:

- 0.2 ml library lysate in 1X Lambda Dilution Buffer and 7% DMSO
- 0.5 ml host strain
- Lambda Library Protocol Handbook (PT10)

TITER: $\geq 10^8$ pfu/ml

CLONING VECTOR: λ gt10

CLONING SITE: EcoRI

PRIMING METHOD: oligo(dT)-primed

HOST STRAIN: C600 Hfr

mRNA SOURCE:
whole embryo (not including placenta
extraembryonic membranes) from a cross between
ICR outbred females and outbred Swiss Webster
males, 11.5 days post-coitus (noon on the day
vaginal plug is 0.5 day post-coitus)

NOTE: No further information on the mRNA source
was made available to CLONTECH.

QUALITY CONTROL DATA

SELECTION CRITERIA: Clear plaques from turbid plaques (nonrecombinant or parental)

ESTIMATED
% OF CLEAR PLAQUES: 86%
(when plated on C600 before amplifying in C600Hfr)

NUMBER OF
INDEPENDENT CLONES: 1.7×10^6

AVERAGE INSERT SIZE: 1.5 kb

INSERT SIZE RANGE: 0.8-4.0 kb

AMPLIFICATION: This library was amplified once in C600Hfr

APPROVED BY:

(PA93650-1)

0003

FOR RESEARCH USE ONLY

Page No. _____

Titer library

0.1

2.1

5.1

10.1

1.5 $\times 10^4$

4.0

3.0

7.1 $\times 10^7$ p.f.u./ μ

Ad library

1:500

1:250000

Plate the cells at 5×10^4 3.75 $\times 10^4$ p.f.u./ μ 1.575 $\times 10^4$ 3.75 $\times 10^4$ p.f.u./ μ

Ad library

1 $\times 10^4$

10:999 dilution

3 $\times 10^4$ p.f.u./ μ = 3.75 $\times 10^4$ p.f.u./ μ need 75 μ Take fresh dilution and plate at 3.75 $\times 10^4$ p.f.u./ μ (2) plates by 10 μ

The plates did not grow in 8 hours I left them overnight returned 11 PM. They had grown to full size & the concentration was 10 fold less.

0004

To Page No. 8

essed & Understood by me,

Date

Invented by

Date

Recorded by

Richard Nelson

DPC

TITLE 5' Search DNA library for

Project No. _____

Book No. _____

From Page No. 83 Probes made for Fred Eletcher to use in screening

PROGRAM # = 13 28 June 91 the elements 2 650 columns
 REGION A: LL-UL = 5-1700 LCR = 0 BKG = .00 % 2 SIGMA = .00
 REGION B: LL-UL = 50-1700 LCR = 0 BKG = .00 % 2 SIGMA = .00
 REGION C: LL-UL = 0-0 LCR = 0 BKG = .00 % 2 SIGMA = .00
 TIME = 1.00 K = 1.000 DIP = SIS
 P# S# TIME CPMA/K %DEV CPMB/K %DEV CPMC/K %DEV SIE SIS FLAGS MIN
 WARNING: NOT NORMALIZED
 13 1 1.00 481546. 29 9757.00 2.02 .00 .00 .000 41.366 160 112
 13 2 1.00 666133. 25 22258.0 1.34 .00 .00 .000 45.390 160 306
 PROGRAM # = 13 23:32
 REGION A: LL-UL = 5-1700 LCR = 0 BKG = .00 % 2 SIGMA = .00
 REGION B: LL-UL = 50-1700 LCR = 0 BKG = .00 % 2 SIGMA = .00
 REGION C: LL-UL = 0-0 LCR = 0 BKG = .00 % 2 SIGMA = .00
 TIME = 1.00 K = 1.000 DIP = SIS
 P# S# TIME CPMA/K %DEV CPMB/K %DEV CPMC/K %DEV SIE SIS FLAGS MIN
 WARNING: NOT NORMALIZED
 13 1 1.00 389178. 32 6839.00 2.42 .00 .00 .000 37.510 160 112
 13 2 1.00 293853. 37 4696.00 2.92 .00 .00 .000 35.396 160 306
 13 3 1.00 293853. 37 4696.00 2.92 .00 .00 .000 35.396 160 306

These probes worked within the positive controls
included in the hybridization. See Fred Eletcher's files

0005

To Page No. 8

Witnessed & Understood by me, <u>WPC</u>	Date	Invented by	Date
		Recorded by <u>WPC</u>	

1.94

MuA embryo

cDNA library

probed w/ A2, C6

and GST- β .

probed 42°C on stalks

washed to 1xSSC, 63°

1° films

from Fred Fletcher

plated this library before Xmas 93

but no more descriptions

0006

Mu. DNA 20-21-83

P. 42 42 22 hrs
 H46 42 0/1 50% STARKS 12100 12100 12100
 Wink AT 6X SSC 12.5 SDS 12100 12100 12100
 63° 1X SSC 12100 12100 12100
 65° 0.1X SSC 12100 12100 12100

exp 3045 4200/89



200 100 1019
 250 150 519
 250 150 519
 250 150 519

Oligo NAME: A2RIB5.28

Sequence Requested by: KOZLOSKY
Project name: ELK

Date Requested:

Date Synthesized:

DNA Sequence (5'-3'):
5'-ATC TTT TTT TGC
CCG CAC TAC AAC AGC
T-3'

PURIFICATION: PHENOL

COMMENTS:
A2 5 PRIME PCR OLIGO FOR
MAKING 3' RIBOPROBE.

A2rib5.28

R7043

1 GATATTACT GCCCGCACTA CAACAGCT

Column 2

9:44:32A

Run ID :

Cycle : 40PLUS CYC

End Frpc: End CE

(DMT = On)

Sequence: 12334

Total bases = 28

A= 8, G= 4, C= 9, T= 7, 5= 0, 6= 0, 7= 0, 8= 0
(mixed bases= 0)

MW: 8489.6

5' GAT ATT TAC TGC CCG CAC TAC AAC AGC T <3'

Purification:

Amount of crude:

O.D.260:

dilution factor:

concentration:

yield:

OPC

all

1.600

1:500

10.09 µg/lx
1,003.9 µg

gel on
back

0027

Oligo NAME:

A2T7.49

Oligo number:

12333

Sequence Requested by:
Project name:

KOZLOSKY
ELK

Date Requested:

Date Synthesized:

DNA Sequence (5'-3'):

5'-TGC GAA TAA TAC
GAC TCA CTA TAG AGA
GAA GGC GCT GAA CCG
CTG GAA C-3'

PURIFICATION: PHENOL

(49 bases)

16A's 14G's
10C's 9T's

COMMENTS:

3 PRIME A2 OLIGO TO PCR
A T7 RIBOPROBE. THIS
OLIGO IS ANTISENSE AND
CONTAINS THE T7
PROMOTER.

A2t7.49



R7044

1 TGC GAA TAA TAC GAC TCA CTA TAG AGA GAA GGC GCT GTAG CGCTGGAAC

Column 1

9:44:31A

Run ID :

Cycle : 40PLUS CYC

End Proc: End CE

(DMT = On ;

Sequence: 12333

Total bases = 49

A= 16, G= 14, C= 10, T= 9, S= 0, 6= 0, 7= 0, 8= 0
(mixed bases= 0)

MW: 15174.8

5' TGC GAA TAA TAC GAC TCA CTA TAG AGA GAA GGC GCT GTA

GGC CTG GAA C <3'

Purification:

OPC

Amount of crude:

au

O.D.260:

276

dilution factor:

1:500

concentration:

4.60 µg/λ

yield:

460 µg

gel on
12334

0028

Oligo NAME: C6RIB05.31

Oligo number:

Sequence Requested by: KOZLOSKY
Project name: ELK

12312

Date Requested:

Date Synthesized:

DNA Sequence (5'-3'): 5'-ACG TAG TCT ACT
GGA ACT CCA GTA ACC
CCA G-3'

(31 bases)

9A's 6G's
10C's 6T's

PURIFICATION: ~~standard~~ OPL

COMMENTS:

5 PRIME PCR FOR C6 RIBO

R7023

Column 1

0:45:43F

Seq ID :

Acid : 40PLUS ETC

End Prod: End CE (DMT = 0n)

Bo Sequence: 12312

Applied Biosystems G 209118

Total bases = 31

A= 9, G= 6, C= 10, T= 6, 5= 0, 8= 0, 7= 0, 8= 0
Mixed bases= 0

W: 9444.2

5' ACG TAG TCT ACT GGA ACT CCA GTA ACC CCA G 3'

Purification: OPL

Amount of crude: all

O.D.260: 0.382

dilution factor: 1-500

concentration: 6.36 ug/lx

yield: 636 ug

get on
12,334

0029

Oligo NAME: C6T7.54
Sequence Requested by: KOZLOSKY
Project name: ELK

Oligo number: 12316

Date Requested:

Date Synthesized:

DNA Sequence (5'-3'): 5'-TGC GAA TAA TAC
GAC TCA CTA TAG CCT
CAA GCA CTG GCC AGA
ACT CTC TGG AGT -3'

(54 bases)

16A's 11G's

15C's 12T's

PURIFICATION: ~~PHENOL~~ OPC

COMMENTS:

C6 3 PRIME FOR C6 RIBO
USE T7 POL.

Applied Biosystems T 453741



R7024

COLUMN 2 SET-UP
VERSION 2.02

USER_NAME:
CYCLES USED: 0.20MG - 1
ENDING METHOD: Trityl ON, Auto
ENDING PROCEDURE: deprime
SEQUENCE NAME: 12316
SEQUENCE LENGTH: 54
DATE:
TIME: 17:37
COMMENT:

5'- TGC GAA TAA TAC GAC TCA CTA TAG CCT CAA GCA CTG

GCC AGA ACT CTC TGG AGT -3'

yield:

OPC
all
0.303
1:50
5.04 ug/μl
57.4 ug

gel on
12.334

0030

IMMUNEX LABORATORY NOTEBOOK

"TABLE OF CONTENTS" FORM

Notebook #: 3388

Date form completed:

Form Completed by: Carl Kozlosky


MOLECULE(S): B61, ELK, ELK-L, HKK,
LeRKs 1, 2, 3, 4, 5, 7

PROJECT(S): R150L

HEKL
CLONE A2
SEQ REQ 1741
DIR= [JOHNSONL.HEKL]

T7 is 5' End
Bg12 into Bam HI

09:13



X s E
 h s
 o P
 2 3
 1

B s
 s
 P
 M
 1

B s
 P
 B1
 F a2
 m n8
 1 26

B s
 s
 r
 F
 1

N s
 P
 B
 2

1
 GGATCTTGGAACGAGACGACCTGCTGGAGAAGCGGGAGCGCGGGCTCAGTCGGGGGGCGGCGGCGGCGGCTCCGGGATGGCGGCGGCTCCGCTG
 CCTAGAACCCTGTCTGTCTGGACGACCTCTCGGCCCTCGCGCCCCGAGTCAGCCCCCGCGCGCGCGCGAGGCCCTACCGCGCGAGGGGAC
 AspLeuGlyThrArgArgProAlaGlyGluAlaGlySerAlaGlyLeuSerArgGlyAlaAlaAlaAlaAlaProGlyMetAlaAlaAlaProLeu

B

B
 s
 P 1 N N B p
 2 P s S D sAB1P H N
 8 B P t r rpa2s a sS
 6 2 2 Y a Fan8s • PP
 1 2 11261 2 Hh
 11
 CCGTGC CGCTGCTGCGCTGCTGGCCCAAGGGCCCGGAGGGGGCGTGGGAAACCGGCATGCGGTGTACTGGAAACAGCT
 GGCACGGCGACGACGGCGACGACCGGGTTCCCGGGCCTCCCGCGACCCCTTTGGCCGTAAGCCACATGACCTTGTGGA
 roValProLeuLeuProLeuLeuAlaGlnGlu

A 1 B 1
 W P P
 N M M
 1 1 1

A 2 R 185.28

A D AA
 v r pv
 1 2 11

201 CCAACCAGCACCTGCGGCGAGAGGGCTACACCGTGCAGGTGAACGTGAACGACTATCTGATATTTACTGCGGCACTACAACAGCTGGGGGGTGGGCC
 GGTTGGTGGTGGACGCCGCTCTCCCGATGTGGCAGCTCCACTTGCACCTTGCTGATAGACCTATAAATGAAGGGCGTGATGTGTGGAGCCCCACCACCGGG

AsnGlnHisLeuArgArgGluGlyTyrThrValGlnValAsnValAsnAspTyrLeuAspIleTyrCysProHisTyrAsnSerSerGlyValGlyPro

B 1
 1

B s B s
 pB s
 B1sPSX D sAB1P B
 a2rsmm r rpa2s s
 n8Faaa a Fan8s B
 261111 2 11261 A g
 1 1 1
 1 1 1
 CGGGGCGGGACCGGGGCCCGAGGCGGGCAGAGCAGTACGTCCTGTACATGGTGAGCCGGCAA CGGCTACCGCACTGCAACGCCAGCCAGGGCTTCAAG
 101 GCCCCGCCCTGGCCCCGGGCGCTCCGCCCGCTCTCGTCAATGCAACGACATGTACCACTGGGGTTGCCGATGGCGTGGACGCTTGCGGTTCGGTCCCGAAGTTC 400
 GlyAlaGlyProGlyProGlyGlyGlyAlaGluGlnTyrValLeuTyrMetValSerArgAsnGlyTyrArgThrCysAsnAlaSerGlnGlyPheLys
 E
 C
 L

[illegible]

0032

TITLE


A2 S29.

Project No. _____

Book No. _____

62

From Page No. _____



To Page No. _____

Witnessed & Understood by me,

opc

Date

Invented by

Carl Norbury

Date


Recorded by

0033

HEK1 132-11, C6-no vector
2491, T7, DPC3266, DPC3267, ~~DPC3274~~, DPC3275
SR1810 KOZLOSKY
file: (BERTLESJ.HEK1)C6.SEQ

With 114 enzymes: *

12:12 . .



8
5
6
81
a2
n8
26
/

A	B
v	c
a	g
l	l

8
P
m
1

1
G C C A G A C C A A A C C G G A C C T C G G G G G G A T G C G G C T G C T G C C C T G C T G C G G A T G T C T C T G G G C G C G T T C C T C G G T C C C T C T G C G C G G G G G T C C A
100
1
G C C A G A C C A A A C C G G A C C T C G G G G G G A T G C G G C T G C T G C C C T G C T G C G G A T G T C T C T G G G C G C G T T C C T C G G T C C C T C T G C G C G G G G G T C C A

a: AlaArgProAsnArgThrSerGlyAlaMetArgLeuLeuProLeuLeuArgThrValLeuTrpAlaAlaPheLeuGlySerProLeuArgGlyGlySerSer

B	
ES	A
pa	C
mA	C
1.1	1

6R1B0-31

E	B	
S	S	D
P	a	S
3	H	a
1	1	1

T
e
h
3
1

101 GCCTCCGGCAGCTAGTCTACTGGAATCCAGTAAACCCAGTTGCTTCGAGGAGACGCCGTGGTGGAGCTGGGCTCAAAGATTACCTAGACATTGTCTG 200
 CGGAGGCGGTGCATCAGATGACCTTGAGGTCAATGGGGTCCAACGAAGCTCTCTCGGGCACCACCTCGACCCGAGGTTCTAATGGATCTGTAACAGAC

a: LeuArgHisValValTyrTrpAsnSerSerAsnProArgLeuLeuArgGlyAspAlaValValGluLeuGlyLeuAsnAspTyrLeuAspIleValCys

	B		B
	sB		s
	ps	E	p
DD	PABluP	DDsPAABB1P	
rr	spa23s	rrpsvac2s	
aa	san86s	aa3saang8s	
22	112611	2211112161	
	///	/	///

E B
a a
e l
l l

DD PAAB
rr spva
aa saan
22 1112
/

[illegible]

a: ProHisTyrGluGlyProGlyProProGluGlyProGluThrPheAlaLeuTyrMetValAspTrpIleGlyTyrHisSerGlnAlaGlyGlyPro

B
S
PB
1sPSX
2rsm
8Fsa
61111
///

E
 C
 O H
 4 a
 7 e

B
S
pH
lg
2i
8A
61

E	B
a	a
e	l
l	l

E
 C
 O H
 4 a
 7 e
 3 2

CGGGCTACAAGCGCTGGGTGTCTCCCTGCCCTTTGGCCATGTTCAATTCTCAGAGAAGATTACAGCGCTTCAACCTTTCTCCCTCGGCTTTGAGTTCT
GCCCCGATGTTTCGCGACCCACACGAGGGACGGGAAACGGTACAAGTTAAGAGTCTCTTTAAGTCGCAAGGTGTGAAAGAGGGAGCCGAAACTCAAGA

a: ArgAlaTyrLysArgTrpValCysSerLeuProPheGlyHisValGlnPheSerGluLysIleGlnArgPheThrProPheSerLeuGlyPheGluPheLeu - 1/1

B	B	B	B
P	P	a	S
m	m	n	F
l	l	l	1
			2
			8
			6

T	
t	EBB
h	apa
3	eml
2	111

¹ 1 1 1 6 2 111
 TACCTCGAGAGACTTACTACTACATCTCGGTGCCCACTCCAGAGAGTTCTGGCCAGTGTCTTGAGCTCCAGGTGTCTCTCTGTCTCAAGGAGAGGAAGTC
 401 ATCGACCTCTCTGAATGATGATGTAGAGCCACGGGTGAGGCTCTCTTAAGACCGGTCAAGAACTCTCAGGTCCACAGACAGAGACCTTCTCTCTCTTCTAG 500

ProGlySerThrTyrTyrTyrIleSerValProThrProGluSerSerGlyGlnCysLeuArgLeuGlnValSerValCysCysLysGluArgLysSer -

Б
5
1
Б1
а2
н
26

E
P
E
I

3

501 TGAGTCAGGTCATCTCTCTGGAGAGTTGAGAGAGTGGCAGATCAGGGTGGGAGGGGGGAGACTCCAGCCCCCTCTGTCTTACTATTACTCTG
ATGCACTGGGCTATGACAAACCTTGGGAGCTCTCTCACCCTGTAGTCCCAACCGCTCCCCCTCTGAGGGTGGGGGAGACAGAGAACGATAATGACGAC

-TCTAG

179.69 = 208.1

TITLE

Cb Sq.

Project No. _____

Book No. _____

66

From Page No. _____

Witnessed & Understood by me,

op

Date

Invented by

Recorded by

Date

To Page No. _____

0035

TITLE Cb T7 Ribo PCR

Project No. _____

Book No. _____

31

From Page No. _____



Cb Binding Region
T7 RNA Pol

Witnessed & Understood by me.

PPL

Date

Invented by

Recorded by

Date

To Page No. _____

0036

TITLE Cb Nth

Project No. _____

Book No. _____

From Page No. _____

< 189 ~ 106Kb W HSB-2



New A2 T7
Riboprobe
Template

To Page No. _____

Witnessed & Understood by me.

OK

Date

Invented by

Recorded by

Date

0037

B
D Es
s ap
a eM
l 11

601 GTGACCTTTGCCCTCTGACCTGCCACGGCCACCTCCGAGACAAAATCCTTGCTGCTTCTTTTCATGGTGTGTCCCGCCGGAGGAGGCCATCCATCCGT
CACTGGAAACGGGAGACTGGACGGTGCCGGTGGAGGCTCTGTTTTAGGAACGACGAAGAGAAAGTACCACGACAGGGCGGCCTCTCCGGTAGGTAGGCA 700

a: ValThrPheAlaLeuEndProAlaThrAlaThrSerGluThrLysSerLeuLeuLeuLeuPheHisGlyAlaValProProGluGluAlaIleHisProSer -

P B
Dp P s
ru s u
am s 3
21 l 6
/ 1

701 CCCTGGGATGCAACATGGGGTCCCAATGCCTGAGGAGAAGACCCCCCAAGGCTGACTCGCTTTCACCAGGGCCACCAGGGCCATCCAGTGTGYATA
GGGACCCTACGTTGTACCCAGGGTTACGGACTCCTCTTCTGGGGGGGGTCCGACTGAGCGAAAGTGGTCCCGGTGGTCCCGGTAGGTACAACRTAT 800

a: LeuGlyCysAsnMetGlySerGlnCysLeuArgArgArgProProProLysAlaAspSerLeuSerProGlyProProGlyProSerSerVal???End -

ATTCTTT
801 ----- 807
TAAGAAA

a: PhePhe -

Enzymes that do cut:

AccI	AlwNI	ApoI	ApaI	AvaI	BalI	BanI	Ban2	BbsI	BglI	Bpu1102I	BpmI	BsaI
BsaHI	BsmI	Bsp1286	BspMI	BsrFI	BstXI	Bsu36I	Dra2	DsaI	EaeI	EarI	Eco473	EcoNI
EcoRI	EcoR5	Hae2	KasI	NarI	NspB2	PpuMI	PssI	PstI	SfiI	SfiI	SmaI	SrfI
StyI	XmaI											

Enzymes that do not cut:

Aat2	Afl2	Afl3	AgeI	ApaLI	AscI	AseI	Asp718	Asu2	Avr2	BamHI	BcgI	BclI
Bgl2	BsaAI	BsaBI	BsiEI	BsiWI	BspEI	BspHI	BssH2	Bst1107	BstE2	Clal	DraI	Dra3
DrdI	Eam1105	Eco571	Esp3I	FspI	HgiAI	Hinc2	Hind3	HpaI	KpnI	MluI	MunI	NcoI
NdeI	NgoMI	NheI	NotI	NruI	NsiI	NspHI	PacI	PflMI	PmeI	PmlI	PvuI	Pvu2
Rsr2	Sall	ScaI	SgrAI	SnaBI	SpeI	SphI	Sse8387	SspI	SstI	Sst2	StuI	SwaI
Tth3I	Tth32	XbaI	XcmI	XhoI	Xho2	Xma3	XmaFI					

GAP of: Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: A2.Pep check: 4723 from: 1 to: 238

TRANSLATE of: a2.seq check: 6473 from: 83 to: 796
generated symbols 1 to: 238.

HEKL

CLONE A2

SEQ REQ 1741

DIR= [JOHNSONL.HEKL] . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 137.9 Length: 246
Ratio: 0.741 Gaps: 6
Percent Similarity: 67.416 Percent Identity: 48.876

Mlerk6.Pep x A2.Pep

16:30 ..

```
1 .....RARANADRYAVYWNRSNRFRQVSAVG 26
      :|::|.|.|.|.|.|.|.|.|.|.|
1 MAAAPLLLLLLLVPVPLPLLAQGPGGALGNRHAVYWNSNQHLRR.... 46
27 DGGGYTVEVSINDYLDIYCPHY.....GAPLPPAERMERYILYMNGE 69
      :|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|
47 ..EGYTVQVNVNDYLDIYCPHYNSSGVGPGAGPGPGGGAEQYVLYMVS RN 94
70 GHASCDHRQRGFKRWE CNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHE 119
      |. .|: .| |.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|
95 GYRTCNASQ.GFKRWE CNRPHAPHSP IKFSEKFQRYSAFSLGYEFHAGHE 143
120 YYYISATPPNVLDRPCLRLKVYV.....RPTNETLYEAPEPIFTSNSSC 163
      |.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|
144 YYYIS.TPTHNLHWKCLRMKV FVCCASTSHSGEKPVP TLPQFTMGPNVKI 192
164 SGLGGCHLFLTTPVVL.WSLLGS*..... 186
      ..|:: . . || | .|: |.
193 NVLEDFEGENPQVPKLEKSISGTSPKREHLPLAVGIAFFLMTFLAS 238
```

GAP of: Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE

DO NOT COPY!

to: C6.Pep check: 8194 from: 1 to: 201

TRANSLATE of: c6.seq check: 6086 from: 53 to: 655
generated symbols 1 to: 201.

HEKL 132-11, C6-no vector

2491, T7, DPC3266, DPC3267, DPC3274, DPC3275

SR1810 KOZLOSKY

file: [BERTLESJ.HEKL]C6.SEQ . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight:	3.000	Average Match:	0.540
Length Weight:	0.100	Average Mismatch:	-0.396

Quality:	118.5	Length:	216
Ratio:	0.637	Gaps:	7
Percent Similarity:	61.988	Percent Identity:	46.199

Mlerk6.Pep x C6.Pep

16:31 ..

```
1 .....RARANAD.RYAVYWNRSNPRFQVSAVGDGGGY 31
      . | : . . | . | | | | . | | | : | :
1 MRLLP LLRTVLWAAFLGSP LRGSSLRHV VYWNSSNPRL . . . . .RGDA 44
32 TVEVSINDYLDIYCPHYGAPLPPAERMERYILYMVNGEGHASCD.HRQRG 80
      . | | : : : | | | | | | | | | : | | : . | . | | : . | :
45 VVELGLNDYLDIVCPHYEGPGPPEGP.ETFALYMDWPGYESCQAEGPRA 93
81 FKRWE CNRP AAPGGPLKFSEKFQLFTPFS LGFEFRPGHEYYYISATPPNL 130
      : | | | | | . | | : . | | | | : | | | | | | | | | | | | | :
94 YKRWVC...SLPFGHVQFSEKIQRFTPFSLGFEFLPGETYYYYISVPTPES 140
131 VDRPCLRLKVYVRPTNETLYEAPEPIFTSNSSCSGLGGCH..... 170
      : . | | | | . | | . . . | . . . : : | : | | : | . .
141 SGQ.CLR LQVSV CCKERKSESAHPVGSPGESGTSGWRGGDTPSPLCLLLL 189
171 LFLTTVPVLW SLLGS* 186
      | : | . . . : | : |
190 LLLLILRLLRIL.... 201
```

GAP of: Mlerk6.Pep che : 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: Elkl.Pep check: 1665 from: 1 to: 240

TRANSLATE of: tele7.seq check: 2210 from: 308 to: 1345
generated symbols 1 to: 346.

[hollingsworth.tele7] ELKL-E7.SEQ + ELKL-E7-3PRIME.SEQ;
req#1262

mGel 97 #2491+ #2492-/ mGel101 DPC2236+ DPC2239+/ mGel104 DPC2258+
DPC2257-/mGel105 DPC2261- /mGel107 DPC2271+ 2272- 2273- 2274+ . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight:	3.000	Average Match:	0.540
Length Weight:	0.100	Average Mismatch:	-0.396

Quality:	82.7	Length:	248
Ratio:	0.445	Gaps:	6
Percent Similarity:	46.067	Percent Identity:	28.652

Mlerk6.Pep x Elkl.Pep 16:46 ..

```
1 RARANADR.....YAVYWNRSNPRFQVSAVG.....DGGGY 31
. ||:.. : :|::: . :::|: . ||.
1 MARPGQRWLKWLVMVWALCRLATPLAKNLEPVSWSLNPFLSGKGL 50
32 TVEVSINDYLDIYCPHYGAPLPPAERMERYILYMVNGEGHASCDHRQRF 81
.: .|. | |||. ||: :|. | . | | ||:|. |. |.
51 VIYPKIGDKLDIICPRAEAGRP....YEYKLYLVRPEQAAACSTVLDPN 96
82 KRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYIYISATPPNLV 131
. ||| |:::|. || |. | :|:|: |:| |. |.
97 VLVTCNR...PEQEIRFTIKFQEFSPNYMGLEFKKHHDYITSTSNGSLE 143
132 D.....RPCLRLKVYVRPTNETLYEAEPIFTSNSSCSGLGGCHLFL 173
: . :|:~::~:~. ||: ||. | :~:::
144 GLENREGGVCRTRTMKIIMKVGQDPNAVTPQLTTSRPSKEADNTVKM.A 192
174 TTVPVLWSLLGS*..... 186
| .|. :~ ||.
193 TQAPGSRGSLGDSGKHETVNQEEKSGPGASGGSSGDPDGFNSKVAL 240
```

GAP of: Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE

DO NOT COPY!

to: Lerk5.Pep check: 8553 from: 1 to: 240

TRANSLATE of: lerk5.leg check: 889 from: 1 to: 1002
generated symbols 1 to: 334.

Coding region of human LERK-5.

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight:	3.000	Average Match:	0.540
Length Weight:	0.100	Average Mismatch:	-0.396

Quality:	83.2	Length:	250
Ratio:	0.447	Gaps:	5
Percent Similarity:	47.727	Percent Identity:	27.841

Mlerk6.Pep x Lerk5.Pep

16:59 ..

```
1 .....HARANADRY....AVYWNRSNPRFQVSAVG DG 28
      .|.. .. :| | | .| | :|
1 MAVRRDSVWKYCWGVLMLVLCRTAISKSI VLEPIYWNSSNSKFL.....PG 45
29 GGYTVEVSINDYLDIYCPHYGAPLPPAERMERYILYMVNCEGHASCDHRQ 78
      .|... : | | | | | . : . . . . | | : | | : : . . | . : .
46 QGLVLYPQIGDKLDIICPKVDS..KTVGQY EYYKVY MVDKDQADRCTIKK 93
79 RGFKRWECNRPAAPGGPLKFSEKFQLFTPFS LGFEFRPGHEYYYISATPP 128
      . . :| | | : : | | . | | | | . | : | | : : | | | . .
94 ENTPLLNC...AKPDQDIKFTIKFQEFSPNLWGLEFQKNKDYYIISTSNG 140
129 NLVD.....RPCLRLKVY 141
      .| : | | |
141 SLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
142 VRPTNETLYEAEPIFTSNSSCSGLGGCHLFLTTPVLWSSLGS*..... 186
      .|..... : | : | . . . . : | : : . . | : : : : : :
191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIV 240
```

Mlerk6.Pep check: 6430 from: 1 to: 186

TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.

WORKING FILE
DO NOT COPY!

to: B61.Pep check: 4381 from: 1 to: 205

TRANSLATE of: b61.seq check: 6304 from: 74 to: 688
generated symbols 1 to: 205.

LOCUS HUMB61 1480 bp ss-mRNA PRI
DEFINITION Human B61 mRNA, complete cds.
ACCESSION M57730 M37476
KEYWORDS intermediate-early response gene. . . .

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight: 3.000 Average Match: 0.540
Length Weight: 0.100 Average Mismatch: -0.396

Quality: 128.5 Length: 212
Ratio: 0.691 Gaps: 4
Percent Similarity: 59.218 Percent Identity: 45.251

Mlerk6.Pep x B61.Pep

16:29 ..

1RARANADRYAVYWNRSNPRFQVSAVGDGGGYTVEVSIN 38
1 MEFLWAPLLGLCCSLAAADRHTVFWNSSNPKFR.....NEDYTIHVQLN 44
39 DYLDIYCPHYGAPLPPAERMERYILYMVNGEGHASCDHRQRGFKRWE CNR 88
45 DYVDIICPHYEDHSVADAAMEQYILYLVEHEEYQLCQPQSKDQVRWQCNR 94
89 PAAPGGPLKFSEKFQLETPFSLGFEFRPGHEYYYISATPPNLVDRPCLRL 138
95 PSAKHGPEKLSEKFQRFTPTLGKEFKEGHSYYYISKPIHQHEDR.CLRL 143
139 KVVYVRP.....TNETLYEAPAPIFTSNSSCSGLGGCHIF.LTTV 176
144 KVTVSGKITHSPQAHVNPQEKRLAADDPEVRVLHSIGHSAAPRLFPLAWT 193
177 PVLWSSLGS... 186
194 VLLLPLLLLQTP 205

lerk6.Pep check: 6430 from: 1 to: 186
TRANSLATE of: mlerk6.seq check: 8999 from: 1 to: 558
generated symbols 1 to: 186.
WORKING FILE
DO NOT COPY!

to: Mc6.Pep check: 7024 from: 1 to: 168

TRANSLATE of: mc6.seq check: 5844 from: 2 to: 505
generated symbols 1 to: 168.
Sequence of murine C6 (LERK-4) as derived from the genomic
clone (3.5 kbp Sst1 fragment).

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgappep.Cmp
CompCheck: 1254

Gap Weight:	3.000	Average Match:	0.540
Length Weight:	0.100	Average Mismatch:	-0.396

Quality:	111.3	Length:	196
Ratio:	0.663	Gaps:	7
Percent Similarity:	65.190	Percent Identity:	45.570

Mlerk6.Pep x Mc6.Pep

16:31 ..

```
1 RARANADRYAVYWNRSNPRFQVSAVGDDGGYTVEVSTNDYLDIYCPHYGA 50
      :...||      ||::|||::|||::
1 .....LLRGDAV.....VEIGFNDYLDIFCPHYES 25
51 PLPPAERMERYILYMVNGEG.HASCDHRQRFKRWECNRPAAPGGPLKFS 99
  ||::: | : |||: .| .|:... ..:|.||:|..| || :|::||
26 PGPPEGP.ETFALYMDWSGYEACTAEGANAFQRWNCMPFAPFSPVRES 74
100 EKFOLETFPSLGFEFRPGHEYYYISATPPNLVDRPCLRLKVYVRPTN.ET 148
   ||:| :|||.||||| ||..|||||...|: .:| ||||. | | ..: :.
75 EKIQRYTPFPLGFEFLPGETYYYISVPTPESPGR.CLRLQVSVCCKESGS 123
149 LYEAPEPI.FTSNSSCSGLGGCH.....LFLTTPVLWSSLGS* 186
   .|:::|: .::|:|: |. | :| :|:|: | .
124 SHESAHPVGSPGESGTSGWRGGHAPSPLCLLLLLLLLPILRLRLVL. 168
```

Mlerk6.Seq check: 8999 from: 1 to: 797

WORKING FILE
DO NOT COPY!

to: A2.Seq check: 9214 from: 1 to: 987

HEKL
CLONE A2
SEQ REQ 1741
DIR= [JOHNSONL.HEKL]

Symbol comparison table: Gencoredisk:[Gcgcore.Data.Rundata]Nwsgapdna.Cmp
CompCheck: 6876

Gap Weight: 5.000 Average Match: 1.000
Length Weight: 0.300 Average Mismatch: 0.000

Quality: 362.8 Length: 1011
Ratio: 0.455 Gaps: 9
Percent Similarity: 56.016 Percent Identity: 56.016

Mlerk6.Seq x A2.Seq 16:33 ..

```
1 .....CGGGCCCGGGCCAACGCTGAC 21
101 TGCCGCTGCTGCCGCTGCTGGCCCAAGGGCCCGGAGGGGCGCTGGGAAAC 150
22 CGATACGCAGTCTACTGGAACCGTAGCAACCCAGGTTTCAGGTGAGCGC 71
151 CGGCATGCGGTGTACTGGAACAGCTCCAACCAGCACCTGCGG..... 192
72 TGTGGGTGATGGCGGCGGCTATACCGTGGAGGTGAGCATCAACGACTACC 121
193 .....CGAGAGGGCTACACCGTGCAGGTGAACGTGAACGACTATC 232
122 TGGATATCTACTGCCCCACACTA.....CGGGGCG 150
233 TGGATATTTACTGCCCCGCACTACAACAGCTCGGGGGTGGGCCCCGGGGCG 282
151 CCGCTGCCCCCGGCTGAGCGCATGGAGCGGTACATCCTGTACATGGTGAA 200
283 GGACCGGGGGCCCGGAGGCGGGGCAGAGCAGTACGTGCTGTACATGGTGAG 332
201 TGGTGAGGGGCAAGCCTCCTGTGACCACCGGCAGCGAGGCTTCAAGCGCT 250
333 CCGCAACGGGTACCGCACCTGCAACGCCAGCCAG...GGCTTCAAGCGCT 379
251 GGGAAATGCAACCGGCCCCGACGCGCCCGGGGGACCCCTCAAGTTCTCAGAG 300
380 GGGAGTGCAACCGGCCGCACGCCCCGCACAGCCCCATCAAGTTCTCGGAG 429
301 AAGTTCCAACCTCTTCACCCCCTTTTCCCTGGGCTTTGAGTTCCGGCCTGG 350
430 AAGTTCCAGCGCTACAGCGCCTTCTCTCTGGGCTACGAGTTCCACGCCGG 479
351 CCACGAATACTACTACATCTCTGCCACACCTCCCAACCTCGTGGACCGAC 400
480 CCACGAGTACTACTACATCTCCACGCCCACTCACAACC...TGCACTGGA 526
```

448 TATGAGGCTCCAGAC . . . CATCTTCACCAGTAACAGCTCCTGC 489
 ||| || | ||| || || ||| ||
 577 GGGGAGAAGCCGGTCCCCACTCTCCCCCAGTTCACCATGGGCCCAATGT 626
 490 AGCGGCCTGGGTGGCTGTACCTCTTCCTCACACCGTCCCTG 532
 | || ||| | || | | | | | |
 627 GAAGATCAACGTGCTGGAAGACTTTGAGGGAGAGAACCCTCAGGTGCCCA 676
 533 TGCTGTGGTCCCTTCTGGGCTCCTAGTGTGAGGCCGGAGAACACCAGCCC 582
 ||| | | || | | | | | | | | |
 677 AGCTTGAGAAGAGCATCAGCGGGACCAGCCCCAAACGGGAACACCTGCCC 726
 583 CACCTGGACCCCGTGACCTTTGCCCTCTGACCTGCCACGGCCACCTCCGA 632
 | | | | | ||| ||| | | | | | |
 727 CTGGCCGTGGGCATCGCCTTCTTCCTCATGACGTTCTTGGCCTCCTAGCT 776
 633 GACAAAATCCTTGCTGCTTCTCTTTCATGGTGCTGTCC CGCCGGA 677
 | | | | | ||| || | | | | | |
 777 CTGCCCCCTCCCCTGGGGGGGGAGAGATGGGGCGGGGCTTGGAAGGAGCA 826
 678 GGAGGCCATCCATCCGTCCCTGGGATGCAACATGGG GT 715
 || ||| | | ||| ||| || ||| |||
 827 GGGAGCCTTTGGCCTCTCCAAGGGAAGCCTAGTGGGCCTAGACCCCTCCT 876
 716 CCCAATGCCTGAGGAGAAGACCCCCCCCCAAGGCTGACT CGCTTTC 761
 ||| || || | | | | | | | | | | | |
 877 CCCATGGCTAGAAGTGGGGCCTGCACCATACATCTGTGTCCGCCCCCTCT 926
 762 ACCAGGGCCACCAGGGCCATCCAGTGTGcaTAATT 797
 ||| || || | | ||| || | |
 927 ACCCCTTCCCCCACGTAGGGCACTGTAGTGGACCAAGCACGGGGACAGC 976

.
 .
 .

Quality: 183.3 Length: 338
 Ratio: 0.554 Gaps: 3
 Percent Similarity: 61.846 Percent Identity: 61.846

Mlerk6.Seq x Mc6.Seq

14:13 ..

```

99 TACCGTGGAGGTGAGCATCAACGACTACCTGGATATCTACTGCOCCACACT 148
   ||||| || || ||||| ||||| || ||||| ||||| ||
20 .GTGGTGGAGCTGGGCTTCAACGATTACCTAGACATCTTCTGCOCCACATT 68
   .
149 ACGGGGCGCGCTGCCCCCGGCTGAGCGCATGGAGCGGTACATCTGTAC 198
   || || || || || || || || || || || || || || ||
69 ATGAAAGGCCAGGGCCCC...CAGAAGGCCCGGAAACCTTTGCATTATAC 115
   .
199 ATGGTGAATGGTGAAGGGGCAC...GCCTCCTGTGACCAACGGGCAGCGAG 245
   ||||| | | ||| || ||||| | | | | || |
116 ATGGTGGACTGGTCAGGCTACGAGGCGCTGCAOGGCAGAGGGGGCAAATGC 165
   .
246 CTTCAAGCGCTGGGAATGCAACCGGCCCGCAGOGCCCGGGGACCCCTCA 295
   |||| ||||| || ||| ||| |||| | || |
166 CTTCCAGCGCTGGAATTGCTCGATGCTTTTGCCCCCTTTCAGCCCTGTTT 215
   .
296 AGTTCTCAGAGAAGTTCCAACCTCTTCACCCCTTTTCCCTGGGCTTTGAG 345
   ||||| ||| | || | || |||| | ||||| |||||
216 GATTCTCAGAAAAGATTTCAGCGCTACACACCCCTTCCCGCTGGGCTTTGAG 265
   .
346 TTCUGGCGCTGGGCACGAATACTACTACATCTCTGOCACACCTCCCAACCT 395
   ||| ||||| | ||||| ||||| || | |||| |
266 TTCTTGCGCTGGAGAGACTTACTACTACATCTCGGTGCCGACTCCGGAGAG 315
   .
396 CGTGGACCGACCCCTGCGTGGGACTCAAGGTTTATG... 430
   | ||| ||||| ||||| |||| | ||
316 TCCTGgCCG...GTGCGTGAAGACTCCAGGTGTCTGTCT 350

```

\$

Quality: 104.9 Length: 411
Ratio: 0.373 Gaps: 1
Percent Similarity: 39.858 Percent Identity: 39.858

Mlerk6.Seq x Lerk5.Seq

14:01 ..

```

      .
      .
      .
140 .....GCCCACACTACGGGGCGCGCTGCCCCCGGCTGAGCG 176
      |   |||   ||   |||||   || |
1890 ATACCCACAGATAGGAGACAAATTGGATATTATTTGCCCCAAAGTGGACT 1939
      .
177 CATGGAGCGGTACATCCTGTACATGGTGAATGGTGAGGGCCACGCTCCT 226
      | | | | | | | | | | | | |
1940 CTAAAACTGTTGGCCAGTATGAATATTATAAAGTTTATATGGTTGATAAA 1989
      .
227 GTGAACACCGGCAGCGAGGCTTCAAGCGCTGGGAATGCAACCGGCC.... 272
      |   | | |||   || | | | | | | |
1990 GAACCAAGCAGACAGATGCACTATTAAAGAAGGAAAATACCOCTCTOCTCAA 2039
      .
273 ...OGCAGCGCCCCGGGGGACCCCTCAAGTTCTCAGAGAAGTTCCAACCTCT 319
      ||   || | | | | | | | | | | | |
2040 CTGTGCCAAACCAGACCAAGATATCAAATTCACCATCAAGTTTCAAGAAT 2089
      .
320 TCACCCCCCTTTTCOCTGGGCTTTGAGTTCCGGCTGGCCACGAATACTAC 369
      ||| ||| | | | | | | | | | | |
2090 TCAGCCCTAACCTCTGGGGTCTAGAATTTTCAGAAGAACAAGATTATTAC 2139
      .
370 TACATCTCTGCCACACCTCCCAACCTGTGGACCGACCTGCCTGOGACT 419
      || ||| | | | | | | | | | |
2140 ATTATATCTACATCAAATGGGTCTTTGGAGGGCCTGGATAACCAGGAGGG 2189
      .
420 C..... 420
2190 AGGGGTGTGCCAGACAAGAGCCATGAAGATCCTCATGAAAGTTGGACAAG 2239

```

HEK/ELK Meeting Minutes

B. Davison in the absence of Doug Cerretti.

Nicole Nelson summarized the recent screening of a murine embryonic cDNA library with a combination of LERKs(A2,C6) plus GSK beta kinase(Fred Fletcher's probe): Hybridization conditions were 42 C in 50% Stark's followed by washes at 63 C, 0.1X SSC.

13 initial positives were obtained of which 4 did not repeat; Nicole will rescreen these using a less stringent wash protocol. Currently, the sequence analysis indicates that the collection contains at least 1 gsk Beta clone, 1 gsk Beta-like clone and interestingly, a new LERK, LERK-6.

All four cysteine residues are conserved while inspection of the carboxy terminal portion of the sequence indicates that LERK-6 fits into the GPI-linked class(similar to LERKS 1,3 and 4). The amino terminus of the protein is apparently lacking about 20 or 25 amino acid residues in the current clone. In the binding region, the LERK-6 DNA sequence displays about 70% identity with A2(LERK 3) corresponding to 288 bp of overlap.

Efforts are now being directed at identification of a source to obtain the human homologue.

REDACTED

REDACTED



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: (301) 231-5520 Telex: 898-055 ATCCNORTH • FAX: 301-770-2587

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Immunex Corporation
Attention: Stephen L. Malaska
Legal Affairs Department
51 University Street
Seattle, WA 98101

Deposited on Behalf of: Immunex Corporation (Docket No. 2826)

Identification Reference by Depositor:

ATCC Designation

Recombinant phage lambda gt10 vector,
clone lambda 13M LERK-6 (murine)

75829

The deposit was accompanied by: ☐ a scientific description ☐ a proposed taxonomic description
indicated above.

The deposit was received
accepted.

by this International Depository Authority and has been

AT YOUR REQUEST:

☒ We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years after the date of deposit, and for a period of at least five years after the most recent request for a sample. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested
viable.

On ~~that~~ date, the culture was

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Bobbie A. Brandon
Bobbie A. Brandon, Head, ATCC Patent Depository

Date: